The HIV-1 encoded apoptogenic protein Vpr induces mitochondrial membrane permeabilization (MMP) via interactions with the voltage-dependent anion channel (VDAC) and the adenine nucleotide translocator (ANT). We have designed a peptide, TEAM-VP, composed of two functional domains, one a tumor blood vessel RGD-like 'homing' motif and the other an MMP-inducing sequence derived from Vpr. When added to isolated mitochondria, TEAM-VP interacts with ANT and VDAC, reduces oxygen consumption and overcomes Bcl-2 protection to cause inner and outer MMP. TEAM-VP specifically recognizes cell-surface expressed a V b 3 integrins, internalizes, temporarily localizes to lysosomes and progressively co-distributes with the mitochondrial compartment with no sign of lysosomal membrane permeabilization. Finally TEAM-VP reaches mitochondria of angiogenic endothelial cells to induce mitochondrial fission, dissipation of the mitochondrial transmembrane potential (DW m ), cytochrome c release and apoptosis hallmarks. Hence, this chimeric peptide constitutes the first example of a virus-derived mitochondriotoxic compound as a candidate to kill selectively tumor neo-endothelia. Within the integrin family, a V b 3 receptors are considered to be an important target for anticancer therapy being upregulated in certain invasive tumors.
Within the integrin family, a V b 3 receptors are considered to be an important target for anticancer therapy being upregulated in certain invasive tumors.
1 a V b 3 recognizes a specific consensus sequence, an RGD motif, which is present in a number of extracellular matrix proteins like vitronectin, fibronectin, fibrinogen and thrombospondin.
2 RGD-containing peptides have been shown to reduce angiogenesis induced by cytokines and to mediate apoptosis in endothelial cells. 3 It appears that RGD peptides that are constrained in a cyclic conformation, show an increased affinity for binding to integrins. 4 One example is the cyclic RGD-4C peptide, a potent binder of a 5 b 1 , a V b 3 and a V b 5 used to selectively deliver doxorubicin to tumor blood vessels 5 and to internalize the amphipatic peptide (KLAKLAK) 2 in endothelial cells resulting in cellular apoptosis. 6 A number of viral genomes have evolved to hijack apoptotic cell death processes. Various virus families encode proteins that target mitochondrial membranes to trigger cell death. Such proteins include HTLV P13II, Influenza virus PB1-F2, HCV P7, HPV E1Ê 4, Hbx and HIV-1 Vpr. 7, 8 These proteins share a structural criterion in that they contain at least one positively charged amphipathic alpha-helix. Vpr encodes a 96-amino acid, 14 kDa protein that performs multiple functions, including the induction of apoptosis. 9 By association with the mitochondrial membrane, Vpr triggers a typical mitochondrial pathway of apoptosis characterized by an early loss of the inner transmembrane potential (DC m ), the release of cytochrome c, the loss of respiratory activity and activation of various caspases including caspases 9 and 3.
9-11 Genetic evidence in yeast, cooperative channel formation in planar lipid bilayer, affinity purification and plasmon resonance studies showed that the C-terminal Vpr moiety (Vpr52-96) binds to the adenine nucleotide translocator (ANT) and may interact with the voltage-dependent anion channel (VDAC). [10] [11] [12] We have suggested that these interactions may explain how Vpr (and derived C-terminal peptides) induces permeability transition. 10, 11 Indeed, the permeability transition pore (PTP) is assumed to be due to the formation of a dynamic multiprotein complex at outer and inner mitochondrial membrane contact sites. 13 The exact composition of the PTP is still unknown but appears to contain VDAC in the outer membrane and is regulated by ANT in the inner membrane, and cyclophilin D (the target for cyclosporin A, CsA), located in the matrix.
In an attempt to generate new angio-toxic molecules as candidates for cancer drug development, we designed chimeric peptides composed of a V b 3 -binding peptides and apoptogenic sequences derived from the mitochondrio-active portion of Vpr. One of these peptides, called TEAM-VP (for Targeted to Endothelial Apoptogenic Mitochondrio-active Vpr-derived Peptide), is composed of the cysteine-cyclised peptide sequence GGCRGDMFGC 4 and a Vpr67-82 sequence derivative. We show here that short Vpr-derived peptides induce both inner and outer mitochondrial membrane permeabilization, and that the cyclic GGCRGDMFGC peptide specifically binds and internalizes in a V b 3 -expressing cells. Moreover, a detailed study of TEAM-VP's cellular effects, reveals that it internalizes specifically in a V b 3 expressing cells through its cyclic RGD motif, leaves the endo-lysosomal compartment to reach mitochondria and induces an intrinsic-like pathway of apoptosis.
Results
Design of chimeric structures to selectively kill a V b 3 -expressing cells. A systematic screen on isolated mitochondria of synthetic Vpr-derived peptides having a potent MMP inducing activity (ED 50 o1 mM) led us to optimize a 16-mer peptide (termed VP) LLFIHFRIGSRHSRIG (Vpr67-82[C76S]), as it is the shortest strongly active, low oxydizable sequence ( Figure 1a) . 11 First we checked the mitochondriotoxicity of this mutated peptide Vpr67-82[C76S].
When added to purified mitochondria, VP induces inner and outer MMP hallmarks including matrix swelling (Figure 1a) , DC m dissipation (Figure 1b) , mitochondrial volume increase ( Figure 1c ) and extramitochondrial release of cytochrome c (Figure 1d ). Swelling is also induced with D VP, in which the amino-acids are in absolute configuration D (Figure 1a) . Replacement of critical arginine (R) residues (R73A and R80A) in VP greatly reduces MMP (mVP; Figure 1a ,b,d). VPinduced MMP is reduced by pre-treatment of mitochondria with the broad spectrum anion channel inhibitor 4,4 0 -diisothiocyanastilbene-2,2 0 -difulfonic acid disodium salt (DIDS) but not with the PTP inhibitor (closer) cyclosporin A ( Figure 1a ). This latter observation may appear surprising since, Vpr-derived peptides were previously found to induce PTP opening through a CsA-sensitive pathway. 10, 11 Modifications in the VP sequence (comparatively to Vpr) such as length and/or single amino-acid changes may explain part of such functional variations (see discussion). Interestingly, in contrast to Vpr52-96, the shorter peptide VP has very low toxicity when added to various cell cultures (not shown). This appears to be due (at least in part) to lower plasma membrane transducing capacities. When VP is linked to the well defined Tat[49-57] peptide transduction domain, the resulting peptide has a high capacity to transduce plasma membranes and efficiently induces cell killing of various cell types including HUVECs (Figure 2a ). Exploring the design of a Vpr-derived peptide with a selective antitumor effect, we constructed bi-functional peptides containing different RGD-derived cyclic peptides Endothelial cell killing by targeted mitochondrio-toxic Vpr-derived peptide A Borgne-Sanchez et al mastoparan, 17 have poor efficacy to kill HUVEC when combined with cycRGD (Figure 2a,b) . As expected killing efficiency of TEAM-VP increases with time in prolonged HUVEC cultures (viability loss at 72 h 480% at 15 mM; data not shown). In order to enhance the apoptogenic properties of TEAM-VP, we also synthetized a peptide containing nonnatural amino acids with absolute configuration D in the 16-mer (VP) portion of TEAM-VP (Figure 2a,b) . As expected, the resulting TEAM-D VP has a stronger cytotoxicity on HUVECs (DL 50 ¼ 6.871.5 mM).
The cycRGD motif contained in TEAM-VP was analyzed for its ability to recognize a V b 3 integrins. Cytofluorometric assessment using FITC-labeled RGD peptides reveal that cycRGD (but not linear RGD nor mutated cycRAD) binds to HUVECs' plasma membrane (Figure 3a ). This binding is specific since an excess of unlabeled cycRGD competes with FITC-cycRGD (Figure 3b Further series of experiments point out interesting properties of TEAM-VP and derived peptides. For instance, VP family peptides bypass the mitochondrioprotective effect of Bcl-xl and Bcl-2 antiapoptotic proteins on isolated mitochondria. Indeed addition of recombinant Bcl-xl and Bcl-2 to isolated mitochondria prevents tBid-induced but not TEAM-VP-induced cytochrome c release (Figure 5d ). Strikingly, such MMP inducing properties and Bcl-2 independence are enhanced using D VP and TEAM-D VP. We then investigated the hypothesis that TEAM-VP might have the same target as Vpr52-96, namely the PTP. 10, 11 It appears that biotinylated TEAM-VP can be used as a tool for affinity-mediated purification of ANT and VDAC from isolated liver mitochondria (Figure 5f ). These results suggest that TEAM-VP is recruited to the PTP via a direct, specific interaction with ANT and/or VDAC. To investigate whether TEAM-VP may also interact with ANT when it kills cells, cultured HUVEC were incubated for 24 h with biotinylated TEAM-VP (which is as efficient as nonmodified TEAM-VP in inducing HUVEC's DC m loss and death; not shown), followed by cell lysis, crude extract preparation and purification of biotinylated-TEAM-VP binding proteins on avidin-agarose. This led to the recovery of ANT (but not HSP-60) by immunoblotting (Figure 5g ). In addition, when added to mitochondria TEAM-VP reduces oxygen consumption (succinate oxidization) in the presence of ADP, in a dose-dependent manner (Figure 5h ). Adding cytochrome c to TEAM-VP-treated mitochondria oxidizing succinate stimulates oxygen uptake indicating that TEAM-VP does not (1) and (4) is shown on the right panels (3 and 6, respectively). Movies corresponding to the right panels are presented in Supplementary Materials. All images are representative confocal microscopy sections. Scale bars, 10 mm Endothelial cell killing by targeted mitochondrio-toxic Vpr-derived peptide A Borgne-Sanchez et al among the three critical arginines (R73,77,80) only partly reduces TEAM-VP toxicity in cellula. 10 In situ detection of cytochrome c reveals a massive release of the protein in the cytoplasm in presence of TEAM-VP at 24 h (Figure 6c) . Interestingly, fluorescence microscopy on TEAM-VP-treated cells (Figure 6c,d ) reveals dramatic changes in the mitochondrial network with small punctiform organelles resembling fragmented mitochondria. 21 This is confirmed by electron microscopy (Figure 6e) showing invaginations of OMM (outer mitochondrial membrane) and mitochondria connected by a narrow neck in cells treated with TEAM-VP or mClCCP, a positive control for fission. Mitochondrial fission appears despite the presence of the pan-caspase inhibitor Z-VADfmk (Figure 6d ) suggesting that TEAM-VP induces early fragmentation of mitochondria, which precedes caspase activation. In conclusion, TEAM-VP induces major cell death associated changes of mitochondria in a V b 3 positive cells.
TEAM-VP-induced cell death presents hallmarks of apoptosis. To ensure that the lysosomal membrane permeabilization process was not at the origin of TEAM-VP-induced cell death, we studied the integrity of lysosomal membranes during treatment with TEAM-VP (Figure 7a ). Clearly, TEAM-VP does not induce the release of the lysosomal protease cathepsin B which codistributes with lysosomes, indicating that there is no massive lysosomal membrane permeabilization (LMP) in the presence of TEAM-VP, contrary to the treatment with UV and the quinolone antibiotic norfloxacin which induces translocation of cathepsin B from lysosomes (positive control for LMP). 22 Accordingly, massive inhibition of catabolic lysosomal proteases with chloroquine and NH 4 Cl and specific inhibition of cathepsin B by Z-FA-fmk do not affect TEAM-VP-induced DC m loss and cell death (Figure 7b ). We further analyzed various cell death parameters, which allow us to chronologically order apoptotic events induced by TEAM-VP (Figure 8a) . DC m dissipation is detected early (16 h) and is not inhibited by the pan-caspase inhibitor Q-VD-OPH. DC m dissipation is followed by phosphatidylserines translocation to the outer leaflet of the plasma membrane (24 h). Hypoploïdy estimated by quantification of the sub-G1-phase cells occurs much later (48 h) and is inhibited by the broad spectrum caspase inhibitors Z-VAD-fmk or Q-VD-OPH (Figure 8a ). When devoid of its targeted moiety VP is less efficient than TEAM-VP due to the lack of recognition of a V b 3 integrins. Increased caspase-3 like activity is detected at 24 h in cytosolic extract from HUVECs treated with TEAM-VP compared to untreated cells (Figure 8b ). In contrast, no increase in caspase-3 like activity is detected in cytosolic extracts from cells cotreated with Q-VD-OPH and TEAM-VP (not shown). We then investigated in detail the appearance of nuclear apoptosis in the presence of TEAM-VP during doseresponse and time-response experiments ( Figure 8c ). Two nuclear stages can be identified: stage I, associated with peripheral chromatin condensation, and stage II in which nuclei are fragmented (Figure 8c, upper panels) . 23 Stages I and II appear in a dose-and time-dependent manner and the formation of stage II nuclei is inhibited by the pan-caspase inhibitor Z-VAD-fmk (Figure 8c , lower panels) contrary to stage I formation (and cell death). Hence, TEAM-VP targets mitochondria to induce caspase-dependent and caspaseindependent nuclear apoptotic events. We further investigated the implication of the proapoptotic proteins Bax and Bak in the VP-induced cell death by using the HCT-116 Bax ( þ /À) (control) and Bax/Bak double knockout cells (Figure 8d ; 24 ). The Bax/Bak (À/À) cell line treated with Tat-VP (C3) for 24 h is sensitive to the peptide and has the same percentage of all death as the control cell line on the criteria of plasma membrane permeabilization (7-AAD þ ) and DC m loss (JC-1 low). This indicates that Tat-VP induces a Bax/ Bak independent cell death.
Discussion
The past 15 years have witnessed an explosion in the basic knowledge of mechanisms regulating apoptosis and the mediators that either trigger or inhibit cell death. Consequently, great interest has emerged in devising therapeutic , TEAM-dVP (2.5 mM) or dVP (2.5 mM) after a 5 min-pretreatment with recombinant Bcl-xl or Bcl-2 (1 mM). Mitochondrial supernatants (left panels) and mitochondrial pellet (right panels) were subjected to immunodetection of cytochrome c. Note that both Bcl-xl and Bcl-2 strongly reduce t-Bid-induced cytochrome c release. (e) TEAM-VP-induced cytochrome c release. Isolated mitochondria were incubated with 1 mM TEAM-VP in the presence (or not) of DIDS (10 mM), or with control peptides (C1, C2 and C3) or with Alamethicin (5 mg/ml), and mitochondrial supernatants were subjected to immunoblot detection of cytochrome c. (f) Affinity purification of PTP components (VDAC and ANT) by biotinylated-TEAM-VP. Mitochondria were exposed for 30 min at RT to 5 mM of biotinylated-CycRGD (negative control), 5 mM of biotinylated-TEAM-VP or 5 mM of biotinylated-Vpr52-96 (positive  control) 10,11 peptides, followed by triton solubilization and purification of proteins interacting with TEAM-VP-biotin-streptavidin-agarose. The whole mitochondrial extract (control) or the streptavidin-recovered proteins were separated by SDS-PAGE followed by immunodetection of Hsp60, VDAC (32 kDa) and ANT (30 kDa; Q18 antibody, Santa Cruz). Western-blot for ANT is constituted by two images from different fields of the same gel. (g) Affinity purification of ANT by biotinylated-TEAM-VP in treated HUVECs. Cells were treated for 24 h with 15 mM of biotinylated-CycRGD, TEAM-VP or C2 peptides. Cell lysates were incubated with streptavidin-agarose for purification of proteins interacting with biotinylated-TEAM-VP. The whole cellular extract (control) or the streptavidin-recovered proteins were separated by SDS-PAGE followed by immunodetection with anti-Hsp60 or a polyclonal anti-hANT-1 antibody. (h) Oxidative properties of isolated mitochondria exposed to TEAM-VP. Oxygen consumption curves after addition of the indicated agents. Numbers along the trace are nanomoles of O 2 consumed per minute per milligram of protein. Note that in the presence of 2 mM TEAM-VP oxygen consumption is strongly reduced (450%) but fully restored by external addition of reduced cytochrome c (4 mM). The inserted histogram shows the percentage of oxygen consumption inhibition with increasing concentrations of TEAM-VP Endothelial cell killing by targeted mitochondrio-toxic Vpr-derived peptide A Borgne-Sanchez et al strategies for modulating the key molecules of life-and-death decisions. 25 The central role of mitochondrial membrane permeabilization (MMP) in mediating necrotic and (intrinsic-) apoptotic processes has led to the idea that mitochondria are reservoirs of potential targets for various therapeutic area including cancer therapy. Some antitumoral compounds with direct MMP-inducing effects have been validated in animal models. This is the case for delocalized lipophilic cations such as F16 or MKT-77. 26 Two rational strategies can be distinguished in the design of anti-tumoral compounds acting directly on mitochondria. One is to identify a target that is present only in tumor mitochondria and then to screen (low molecular weight) drugs acting on this specific target. Although various PTP components or other mitochondria-associated proteins are selectively upregulated in tumor cells, druggable MMP-inducing compounds being truly selective for tumor mitochondria have still not been identified. A second strategy is to select natural or xenobiotic Endothelial cell killing by targeted mitochondrio-toxic Vpr-derived peptide A Borgne-Sanchez et al compounds/chemical structures having a potent MMP-inducing effect on any type of mitochondria, and then to deliver selectively such molecules into cancer cells or alternatively into tumor-related neovasculature. As a proof of concept for such targeting strategy, Ellerby et al., 6 have shown that when used in the systemic treatment of mice a chimeric peptide consisting of a tumor blood vessel 'homing' motif, linked to the (KLAKLAK) 2 peptide that disrupts mitochondrial membranes, was selectively toxic to angiogenic endothelial cells and showed anticancer activity.
The present study describes in vitro and in cellula properties of a new chimeric peptide TEAM-VP which is composed of a cyclic RGD peptide motif and a small sequence derived from HIV-1 Vpr (termed VP). Using such a peptide we showed the following properties: (1) Both VP and TEAM-VP interact with ANT and/or VDAC to induce mitochondrial swelling, DC m loss, cytochrome c release and reduction of oxygen consumption. (2) TEAM-VP efficiently kills a V b 3 expressing cells (i.e. HUVECs, HMVECd, A375M), but has no effect on a V b 3 negative cells including peripheral blood mononuclear cells. The early internalization route of TEAM-VP in HUVEC cells is in the line with published reports on cycloRGDfK peptides, 27, 28 thus indicating that a mitochondriotoxic part can be added without to put a damper on RGD binding and internalization through a V b 3 receptors. Distribution in lyso- somes has already been observed for other RGD-peptides like cycloRGDfK, 27, 28 but in our study confocal microscopy clearly shows that TEAM-VP reaches mitochondria after its release from lysosomes without degradation. This is the first detailed study showing microscopic evidence that RGDcontaining peptide reaches its targeted intracellular compartment. It is unclear how TEAM-VP escapes from lysosomes. One hypothetic explanation comes from the observation at 24-h treatment of a massive fusion of lysosomes or late endosomes during which the vesicular membranes might be fragilized, thus allowing the peptide to escape. Another possibility would be related to membrane-destabilizing capabilities of the positively charged alpha-helical amphipathic VP-peptide structure. 29, 30 Whatever is the case, there is no massive lysosomal membrane permeabilization in TEAM-VPtreated cells and cell death still occurs when lysosomal proteases are inhibited. This indicates that the TEAM-VPinduced apoptotic process is not characterized by an escape of active lysosomal proteases in the cytoplasm. In addition, TEAM-VP-induced cell death is not inhibited even partially by Endothelial cell killing by targeted mitochondrio-toxic Vpr-derived peptide A Borgne-Sanchez et al autophagy inhibitors like 3-methyladenine and bafilomycin A1 (data not shown) thus arguing against the possibility of an autophagy-related TEAM-VP-induced cell death. 22, 31 Although Tat-VP does not require Bax/Bak to kill HCT-116 colon carcinoma cells, primary endothelial cell death triggered by TEAM-VP is characterized by classical apoptotic events such as mitochondrial changes (DC m loss, cytochrome c release, fission), caspase-3 activation, phosphatidylserine exposure and nuclear apoptosis. There is evidence that some RGD-derived peptides might trigger apoptosis by direct caspase-3, -8 or -9 activation in an anchorage-independent manner. 32, 33 Caspases-3 and -8 contain a potential RGDbinding motif allowing interaction with RGD peptides and subsequent autoprocessing and activation of these enzymes. 32 Although it is not excluded that such an interaction exists with TEAM-VP, low or absent apoptosis hallmarks in HUVECs treated with the cyclic RGD domain alone or a VP-mutated version of TEAM-VP (see the control peptide termed C2) strongly suggest that the RGD sequence is not apoptogenic in the context of TEAM-VP.
When added to isolated mitochondria, TEAM-VP and TEAM-D VP are able to bypass the protective effects of cyclosporin A, and of the antiapoptotic Bcl-2 and Bcl-xl proteins. These results contrast with those obtained with Vpr1-96, Vpr52-96 and the shorter sequence Vpr71-82 that induce MMP in a CsA-and Bcl-2-dependent manner. 10, 11 However, similar to native Vpr peptides, 10, 11 TEAM-VP interacts with both ANT and VDAC (Figure 5f,g ). Vpr peptides also form alpha-helical structures 12, 30 and were shown to interact with planar lipid bilayers to form cation-selective channels. 34 During initial screening of Vpr-derived peptides, we selected VP because it has the strongest efficacy to induce swelling and DC m on isolated mitochondria. It is highly probable that minor modifications in the Vpr-sequence will influence the relative contributions of VDAC, ANT and mitochondrial lipids during mitochondrial membrane permeabilization induced by these peptides. Recently, Sabbah et al.
12
using cross-linking experiment and surface plasmon resonance confirmed the Vpr/ANT interaction and proposed a tridimensionnal model for the Vpr-ANT complex. Interestingly docking program and dynamic simulations have led these authors to suggest that both Cys76 and Arg80 within Vpr are important for the interaction with ANT. This fits with our data since within TEAM-VP the cys76 is replaced by a serine, TEAM-VP interacts with ANT (Figure 5f ,g) and both VP and TEAM-VP-induced swelling are insensitive to CsA ( Figures  1a,5a,b) . When we used the mVP and TEAM-mVP (C2) control peptides in which C76 and R80 are replaced by Ser and Ala, respectively, we found that TEAM-mVP does not interact with ANT in HUVECs and that mVP and TEAM-mVP do not induce an MMP effect (Figures 1a,b,5b) .
These TEAM-VP peptide properties may be an important advantage from a therapeutic point of view since Bcl-2 overexpression is frequently a causal factor in tumor resistance to chemotherapy, and since Bcl-2 is also upregulated in angiogenic endothelial cells 35, 36 and in a v b 3 -expressing invasive melanoma (reviewed by Seftor et al 37 ) . It should be noted that when used in vitro to kill HUVECs, the TEAM-D VP LD 50 appears 10 fold superior to the LD 50 of the CNGRCGG-D [KLAKLAK] 2 anticancer peptide described by Ellerby et al. 6 As they have demonstrated efficacy in vivo in murine models of tumor growth, one can conclude that TEAM-D VP is an interesting candidate for further in vivo investigations.
Together, our data with TEAM-VP constitute the first example of viral-derived synthetic peptides capable of selectively killing a V b 3 -expressing cells through a VDAC/ ANT-related mitochondrial targeting. Hence, it will be of great interest to evaluate the in vivo efficacy of TEAM-VP (alone or combined with known anticancer agents) to control tumor growth. A number of viruses from various families encode proapoptotic sequences that directly interact with mitochondria. 7, 8 It will be an exciting challenge to systematically explore viral genomes as a source of peptide-based structures to design new anticancer compounds acting directly on mitochondria. (1-14), TEAM-VP and all variants or fragments described in Figure 2a were synthesized by Neosystem (Strasbourg, France) or alternatively Epytop (Nimes, France), using classical automated solid-phase synthesis and purification by reverse-phase HPLC. The synthesis of VP and TEAM-VP derivatives in D-configuration was carried out with the same strategy. All peptides were synthesized with carboxy-terminal amidation and with a free amino-terminal extremity or alternatively NH 2 -terminal biotinylation. RGD-containing peptides were or not subjected to cyclization via cystein oxidation. In some cases NH 2 -terminal FITC peptide conjugates were constructed. All peptides were analyzed by electrospray mass spectrometry and found to be 485% pure. Stock solution (sterile H 2 O, 1 mM) were prepared from lyophilized peptides, aliquoted and stored frozen at À801C. MMP inhibitors used are: 4,4 0 -diisothiocyanastilbene-2,2 0 -difulfonic acid disodium salt (DIDS; Sigma Aldrich; 2-16 mM), cyclosporin A (CsA; BIOMOL Research Lab Inc.), recombinant Bcl-xl (Oncogenet Research products; 1 mM) and recombinant Bcl-2 (Oncogenet Research products; 1 mM).
Preparation of mitochondria and assessment of mitochondrial parameters. Liver mitochondria were isolated from 3-4 week old Balb-c mice (IFFA CREDO) as described previously. 38 Mitochondria were also isolated from HeLa cells (3 Â 10 6 cells) using a protocol adapted from reference. 39 Briefly, cells were harvested with PBS containing 1 mM EDTA, centrifuged at 750 g for 10 min, washed and resuspended in isotonic MB buffer (210 mM mannitol, 70 mM sucrose, 1 mM EDTA and 10 mM HEPES, pH 7.5) supplemented with protease inhibitors. Cells were broken by 10 passages through a 27G Â 3/4 00 0.4 Â 20 mm needle fitted on a 2.5 ml-syringe. The suspension was centrifuged at 1700 Â g at 41C for 2 min. Cell break was observed by microscopy. Supernatants were pooled and centrifuged at 10 000 Â g at 41C for 10 min and mitochondrial pellet resuspended in MB buffer at 2 mg/ml of proteins. For detection of large amplitude swelling, liver mitochondria (100 mg of protein/ml) were incubated for 15-30 min with peptides or MMP-inducing drugs in 1 ml buffer A (200 mM sucrose, 1 mM H 3 PO 4 , 5 mM succinate, 10 mM MOPS, 2 mM rotenone and 10 mM EGTA, pH 7.4). Swelling was determined by measuring absorbance at 545 nm with an Ultrospec 3300 pro spectrofluorometer (Amersham Pharmacia Biotech). 38 The percentage of specific swelling was calculated as follows: (A init ÀA reagent ) 100/(A init ÀA Ca2 þ ) where A Ca2 þ , A reagent and A init correspond to the absorbance value obtained for CaCl 2 -treated, reagenttreated and untreated mitochondria, respectively. Mitochondrial transmembrane potential (DC m ) was assessed by incorporation of 5,5 0 ,6,6 0 ,-tetrachloro 1,1,3,3 0 -tetraethylbenzimidazolylcarbocyanine iodide (JC-1; excitation 488 nm; emission 525-535 nm (low DC m ) and 560-605 nm (high DC m ); Molecular Probes; 1 mM) and flow cytometry acquisition with a FACScalibur (Becton Dickinson) as described previously. 38 For the determination of cytochrome c release, mitochondria (30 mg proteins) isolated from liver were incubated with 5 mg/ml Alamethicin (positive control) or 1 mM of peptide in the presence or not of DIDS (5 mM) in buffer A for 30 min at RT. After centrifugation at 6800 Â g for 10 min, the mitochondrial pellet was frozen for subsequent analysis. Alternatively, mitochondria (30 mg proteins) isolated from HeLa cells were incubated in the presence of t-Bid (gift from Professor JC Martinou) or peptide for 20 min at 371C in buffer B (125 mM KCl, 4 mM MgCl 2 , 5 mM NaHPO 4 , 5 mM succinate, 0.5 mM EGTA, 15 mM Hepes, pH 7.4 and 5 mM rotenone). After a 7 min-centrifugation at 10 000 Â g, proteins contained in supernatant and in resuspended mitochondrial pellet were run on SDS-PAGE (12%) and transferred to Hybond-P (Amersham Biosciences) in a Mini Protean II system (Biorad) for 1 h at 100 V. Subsequently the membrane was blocked for 1 h with 5% low fat milk in TBS-0.1% tween-20 (TBST) and incubated overnight with anti-cytochrome c monoclonal antibody (BD Bioscience Pharmingen; 1/500). After 1 h washes with TBST, the membrane was treated with horseradish peroxidasecoupled anti-mouse IgG (Amersham; 1/2000) for ECL detection (Amersham).
Affinity purification of PTP components. For trapping on isolated mitochondria, mouse liver mitochondria (250 mg of protein/100 ml, in buffer A) were incubated for 20 min at RT with 5 mM of biotinylated peptides. Mitochondria were washed once in buffer A and the pellet was lysed with 150 ml of buffer C (20 mM Tris-HCl, pH 7.6, 400 mM NaCl, 50 mM KCl, 1 mM EDTA, 0.2 mM PMSF, aprotinin (100 U/ml), 1% triton X-100 and 20% glycerol). For trapping on HUVECs, the cells were treated for 24 h with 15 mM of biotinylated peptides. Cells were harvested and lysed with 150 ml of buffer C. The liver mitochondrial extracts and HUVEC cellular extracts were diluted with 300 ml PBS plus 1 mM EDTA before addition of 50 ml streptavidin-agarose (Pierce). After 2 h incubation at 41C in a roller drum, the beads were washed (5 Â ) batchwise with PBS plus 1 mM EDTA and resuspended in 50 ml of 2 Â Laemmli sample buffer. Proteins were analyzed by Western blot using (1) for liver mitochondria: mouse monoclonal IgG 2b anti-Porin 31HL (VDAC; clone Ab-2; Calbiochem; 1/2000), goat polyclonal IgG anti-ANT (Q18; Santa Cruz; 1/500) or mouse monoclonal IgG anti-Hsp60 (clone LK1; Sigma; 1/1000) and (2) for HUVEC: mouse monoclonal IgG anti-Hsp60 (clone LK1; Sigma; 1/1000) or rabbit polyclonal IgG anti-hANT. We obtained this anti-hANT polyclonal antibody after immunization of rabbits with the 21-mer peptide GVYDTAKGMLPDPKNVHIFVS corresponding to the human isoform 1 of ANT, region 193-213; 1/500).
Assessment of apoptosis parameters. For DC m dissipation determination, the JC-1 dye (1 mM; Molecular Probes) was used; for plasma membrane permeabilization assessment, 7-Aminoactinomycin D (10 mg/ml; 7-AAD; Sigma Aldrich) was employed; for phosphatidylserine exposure determination, human recombinant Annexin-V-FITC (1/100; Immunotech) was used. The hypoploidy frequency was determined by propidium iodide (PI, 50 mg/ml) staining of ethanol-permeabilized cells treated with RNase (Sigma Aldrich, 500 ng/ml) supplemented with 5 mM glucose for 1 h at RT. For each sample, around 10 and observed on an inverted Leica DM IRB microscope. Alternatively, mitochondria were labeled with 60 nM MitoTracker s green (Molecular Probes) and fission detected by fluorescence microscopy. For caspase-3 fluorimetric assay, cytosolic extracts were prepared as described. 40 Cytosolic proteins (4 mg) were preincubated for 15 min at 371C with or not N-benzyloxycarbonyl-Asp-Glu(OMe)-His-Asp(OMe)-fluoromethylketone (Z-DEVD-fmk; ICN; 20 mM) before addition of caspase-3 substrate Ac-DEVD-AMC (BIOMOL Research Lab Inc.; 10 mM) for 2 h at 371C in a 200 ml-final volume. Fluorescence was measured (excitation 360 nm; emission 465 nm) using a Genios spectrofluorometer (Tecan).
Phenotyping and binding to integrins. HUVEC cells were trypsinized, washed with PBS and fixed in 1% paraformaldehyde in PBS with 1% BSA and 0.1% NaN 3 for 30 min at 41C. After washes with PBS cells were incubated for 30 min at RT with PE-conjugated mouse monoclonal anti-a V b 3 (clone 23C6; BD Pharmingen; 1/25) or PE-conjugated mouse monoclonal anti-a V b 5 (clone P1F6; Chemicon; 1/50) or mouse IgG 1 R-PE control (Cymbus Biotechnology LTD) in PBS with 1% BSA and 0.1% NaN 3 . Cells were washed and analyzed for integrin expression levels by flow cytometry. For binding assays, cells were incubated for 45 min at RT or 41C with 0.5-2 mM FITC-labeled peptide. For competition assays, cells were preincubated for 30 min at RT with unlabeled competitive peptides in excess before addition of FITClabeled peptide for a 45 min-incubation. In each case, cells were rinsed with PBS, trypsinized, washed twice with PBS and analyzed by flow cytometry.
Peptide routing. Peptide internalization by endocytosis was studied by treating cells for 15 min-5 h with 2.5 mM peptide and 1 mg/ml rhodamine B isothiocyanatedextran 40S beads (Sigma Aldrich) after or not a 30 min-pretreatment with 5 mM NaN 3 and 50 mM 2-deoxyglucose inducing ATP depletion. Cells were labeled with Hoechst 33342 (Sigma Aldrich; 2 mg/ml) before observation on an inverted Leica DM IRB fluorescence microscope. For immunofluorescence analysis, peptidetreated cells were fixed in 4% paraformaldehyde in PBS for 30 Electron microscopy. Isolated mitochondria were fixed in 3.2% glutaraldehyde in 0.1 M Soerensen buffer (0.1 M phosphate, pH 7.2; Prolabo) for 16 h at 41C, then sample was prepared as described. 38 HUVEC cells were fixed with 2% glutaraldehyde in 0.1 M Nacacodylate buffer, pH 7.2 for 3 h at 41C. After washes in the same buffer, specimens were then postfixed with 1% osmium tetroxide containing 1.5% potassium cyanoferrate, dehydrated in gradual ethanol (30-100%) and embedded in Epon. Thin sections (70 nm) were collected onto 200 mesh cupper grids, counterstained with uranyl acetate and lead citrate before examination with a Philips CM12 transmission electron microscope at 80 kV.
Polarographic study. Purified mitochondria were incubated in a magnetically stirred 1.5 ml cell with a Clark type oxygen electrode (Hansatech) thermostated at 371C, in 500 ml of a medium consisting of 0.3 M mannitol, 10 mM phosphate buffer (pH 7.3), 10 mM KCl, 5 mM MgCl 2 and 1 mg/ml BSA as previously described. 41 Respiratory chain complexes activities were measured 4 min after TEAM-VP addition using standard procedure. 41 
